Holen Sie sich die Stockscreener-App
15.97
3.43%
0.53
Handel nachbörslich:
15.97
Schlusskurs vom Vortag:
$15.44
Offen:
$15.42
24-Stunden-Volumen:
99,669
Relative Volume:
0.86
Marktkapitalisierung:
$139.81M
Einnahmen:
$123.24M
Nettoeinkommen (Verlust:
$136.00K
KGV:
-798.50
EPS:
-0.02
Netto-Cashflow:
$-148.99M
1W Leistung:
+15.85%
1M Leistung:
+27.05%
6M Leistung:
-4.93%
1J Leistung:
-3.56%
1-Tages-Spanne:
$15.14
$15.99
1-Wochen-Bereich:
$14.06
$15.99
52-Wochen-Spanne:
$6.53
$26.40
Seres Therapeutics Inc Stock (MCRB) Company Profile
Firmenname
Seres Therapeutics Inc
Sektor
Branche
Telefon
617 945 9626
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie MCRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
15.97 | 127.20M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-08 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-21 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-23 | Herabstufung | Goldman | Neutral → Sell |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-03-05 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-11 | Hochstufung | Jefferies | Hold → Buy |
| 2019-04-30 | Eingeleitet | Jefferies | Hold |
| 2018-10-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-08-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-01 | Bestätigt | FBR & Co. | Outperform |
| 2016-08-12 | Bestätigt | FBR Capital | Outperform |
| 2016-08-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Bestätigt | H.C. Wainwright | Buy |
| 2016-07-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-03-30 | Eingeleitet | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | Guggenheim | Buy |
| 2016-01-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-07-21 | Eingeleitet | Goldman | Neutral |
| 2015-07-21 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
Seres Therapeutics Inc. Bounces Off Moving Average SupportReal Trader Watchlist of Hot Stocks Released - metal.it
Seres (MCRB) Q2 Loss Narrows 34% - AOL.com
Seres Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Seres Therapeutics shares fall 1.90% after-hours following Q2 2025 earnings call. - AInvest
Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics - TipRanks
Seres Therapeutics outlines global Phase II SER-155 trial with 248-patient enrollment amid partnership talks - MSN
Seres Therapeutics Reports Q2 2025 Financial Results - TipRanks
Seres Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Seres Therapeutics: Unpacking Strategic Contradictions in Partnerships and FDA Engagements - AInvest
Seres Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MCRB) - Seeking Alpha
Transcript : Seres Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Sana Biotechnology shares fall 14.12% after-hours following Seres Therapeutics' board changes and clinical advancement updates. - AInvest
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Seres Therapeutics reports larger-than-expected Q2 loss By Investing.com - Investing.com South Africa
Earnings call transcript: Seres Therapeutics reports larger-than-expected Q2 loss - Investing.com
Seres Therapeutics quarterly loss per share $2.27 - MarketScreener
Seres Therapeutics August 2025 slides: SER-155 shows 77% infection reduction - Investing.com
Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share - Yahoo Finance
Seres Therapeutics: A High-Conviction Biotech Buy Amid Clinical and Strategic Momentum - AInvest
Seres Therapeutics Reports Second Quarter 2025 Financial Results - GuruFocus
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance
Seres Therapeutics Inc. Stock Analysis and ForecastAchieve consistent profits with proven methods - Jammu Links News
Is Seres Therapeutics Inc. a growth stock or a value stockRapid portfolio appreciation - Jammu Links News
Is Seres Therapeutics Inc. a good long term investmentAchieve breakthrough gains with smart trades - Jammu Links News
How does Seres Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - Jammu Links News
What are Seres Therapeutics Inc. company’s key revenue driversConsistent high-yield stocks - Jammu Links News
When is Seres Therapeutics Inc. stock expected to show significant growthInvest confidently with real-time data - Jammu Links News
What are analysts’ price targets for Seres Therapeutics Inc. in the next 12 monthsBuild a diversified portfolio for maximum returns - Jammu Links News
Should I hold or sell Seres Therapeutics Inc. stock in 2025Build a portfolio that grows with the market - Jammu Links News
What analysts say about Seres Therapeutics Inc. stockUnmatched profit potential - Jammu Links News
What makes Seres Therapeutics Inc. stock price move sharplyBuild wealth with steady, reliable stocks - Jammu Links News
Why is Seres Therapeutics Inc. stock attracting strong analyst attentionRetirement Planning Entry Points For Consistent Profits - Jammu Links News
Is Seres Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - metal.it
Seres Therapeutics: Speculative Gem with FDA Breakthrough Potential - AInvest
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough - Seeking Alpha
Why Seres Therapeutics Inc. stock attracts strong analyst attentionEntry Zone Strategy for Consistent Profit Shared - metal.it
What institutional investors are buying Seres Therapeutics Inc. stockPhenomenal wealth increase - Jammu Links News
How many analysts rate Seres Therapeutics Inc. as a “Buy”Build wealth with reliable stock picks - Jammu Links News
Will Seres Therapeutics Inc. Recover After Recent DeclineStock Market Entry Timing Signals Revealed - metal.it
What is the dividend policy of Seres Therapeutics Inc. stockSkyrocketing returns - Jammu Links News
Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):